In men with benign prostatic hyperplasia (BPH) who develop refractory hematuria where prostatic bleeding has been identified as the source — and other causes have been systematically excluded — an evidence-based pharmacological approach is available. The clinical goal is reduction or cessation of hematuria.
Refractory hematuria due to prostatic bleeding in the setting of BPH, after exclusion of other causes of hematuria. This defines a specific patient population for whom a targeted treatment strategy is supported by clinical evidence.
Evidence supports 5-alpha reductase inhibitor (5-ARI) therapy as an appropriate and effective treatment alternative in this setting. The full structured protocol — including which agent is used and how — is available via the link below.
Reduction or cessation of hematuria, with a reduced likelihood of recurrent prostatic bleeding.
After exclusion of other causes of hematuria, 5-ARIs may be an appropriate and effective treatment alternative in men with refractory hematuria presumably due to prostatic bleeding.
It was noted that men with prostate-related bleeding responded to finasteride therapy with a reduction or cessation of such bleeding and a reduced likelihood of recurrent bleeding.
View source ↗